Schizophrenia: key endpoint results by drug
The key endpoints of Schizophrenia trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Schizophrenia page.
PANSS total, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Aripiprazole (Abilify Maintena) | -21.5 | -10.3 | −11.2 | 400/300 mg · wk 6 · n 162 | NCT01663532 Phase 3, primary |
| Aripiprazole (Abilify) | -26.7 | -21.2 | −5.5 | 10 mg/day · wk 6 · n 99 | NCT00102063 Phase 3, primary |
| Aripiprazole lauroxil (Aristada) | -21.8 | -9.8 | −12 | 882 mg · wk 12.14 · n 204 | NCT01469039 Phase 3, primary |
| Asenapine | -21.7 | -16.2 | −5.5 | 5 mg BID · wk 6 · n 111 | NCT01617187 Phase 3, primary |
| Brexpiprazole (Rexulti) | -16.6 | -13.5 | −3.1 | 2 mg · wk 6 · n 179 | NCT01393613 Phase 3, primary |
| Cariprazine (Vraylar) | -23 | -14.3 | −8.7 | 6.0mg · wk 6 · n 154 | NCT01104766 Phase 3, primary |
| Iloperidone (Fanapt) | -12 | -7.1 | −4.9 | wk 4 · n 283 | NCT00254202 Phase 3, primary |
| LB-102 (methylated amisulpride) | -14.3 | -9.3 | −5 | 50 mg QD · wk 4 · n 107 | NCT06179108 Phase 2, primary |
| Lumateperone | -14.6 | -15.1 | +0.5 | 42 mg · wk 6 · n 162 | NCT02469155 Phase 3, primary |
| Lurasidone | -26.5 | -10.3 | −16.2 | 160 mg · wk 6 · n 121 | NCT00790192 Phase 3, primary |
| Olanzapine (Weltruza) | -21.9 | -12.2 | −9.8 | 531 mg · wk 8 · n 165 | NCT05693935 Phase 3, primary |
| Olanzapine (Zyprexa) | -8.8 | 4.5 | −13.3 | wk 4 · n 21 | NCT00686998 Phase 2, primary |
| Olanzapine/samidorphan (Lybalvi) | -23.9 | -17.5 | −6.4 | wk 4 · n 132 | NCT02634346 Phase 3, primary |
| Paliperidone (Invega) | -9.8 | -7.9 | −1.9 | wk 6 · n 54 | NCT00518323 Phase 3, primary |
| Paliperidone palmitate (Invega Sustenna) | -13.2 | -2.9 | −10.3 | 150 mg eq. · wk 13 · n 160 | NCT00590577 Phase 3, primary |
| Paliperidone palmitate (Invega Trinza) | -1.8 | -1.6 (PP3M) | — | wk 52 · n 473 | NCT03345342 Phase 3, secondary |
| Perseris | -16.5 | -9.2 | −7.2 | 120 mg · wk 8 · n 114 | NCT02109562 Phase 3, primary |
| Pimavanserin | -15.3 | -13.4 | −1.9 | wk 6 · n 193 | NCT02970292 Phase 3, primary |
| Quetiapine (Seroquel XR) | -24 | -15.9 | −8.1 | wk 6 · n 150 | NCT01810380 Phase 3, primary |
| Quetiapine (Seroquel) | -24 | -15.9 | −8.1 | wk 6 · n 150 | NCT01810380 Phase 3, primary |
| Risperidone (Risperdal Consta) | -9.3 | -1.1 (Quetiapine) | — | wk 104 · n 326 | NCT00216476 Phase 3, secondary |
| Risperidone (Risperdal) | -16.5 | -9.2 | −7.2 | 120 mg · wk 8 · n 114 | NCT02109562 Phase 3, primary |
| tocilizumab | -0.5 | -5.3 | +4.8 | wk 12 · n 19 | NCT02034474 Phase 4, primary |
| Ulotaront | -18.1 | -14.3 | −3.8 | 100 mg · wk 6 · n 152 | NCT04092686 Phase 3, primary |
| Xanomeline/trospium chloride | -14.3 | -12.2 | −2.1 | wk 6 · n 190 | NCT05145413 Phase 3, primary |
Drugs checked with no result here: 48 not reported, 10 trial running, 11 not posted.
CGI-S, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Aripiprazole (Abilify Maintena) | -1.2 | -0.5 | −0.7 | 400/300 mg · wk 6 · n 162 | NCT01663532 Phase 3, secondary |
| Aripiprazole (Abilify) | -1.2 | -0.9 | −0.3 | 10 mg/day · wk 6 · n 99 | NCT00102063 Phase 3, secondary |
| Aripiprazole lauroxil (Aristada) | -0.5 | -0.9 | +0.4 | 441-441 mg · wk 52 · n 80 | NCT01626456 Phase 3, secondary |
| Asenapine | -1.2 | -1 | −0.2 | 5 mg BID · wk 6 · n 111 | NCT01617187 Phase 3, secondary |
| Brexpiprazole (Rexulti) | -1.0 | -0.8 | −0.2 | 2 mg · wk 6 · n 180 | NCT01393613 Phase 3, secondary |
| Cariprazine (Vraylar) | -1.5 | -1 | −0.5 | 6.0mg · wk 6 · n 154 | NCT01104766 Phase 3, secondary |
| LB-102 (methylated amisulpride) | -0.7 | -0.4 | −0.3 | 50 mg QD · wk 4 · n 91 | NCT06179108 Phase 2, secondary |
| Lumateperone | -0.8 | -0.5 | −0.3 | 42 mg · wk 4 · n 148 | NCT02282761 Phase 3, secondary |
| Lurasidone | -1.1 | -1 | −0.1 | 40mg · wk 6 · n 122 | NCT00549718 Phase 3, secondary |
| Olanzapine (Weltruza) | -1.2 | -0.7 | −0.5 | 531 mg · wk 8 · n 165 | NCT05693935 Phase 3, secondary |
| Olanzapine (Zyprexa Relprevv) | -0.4 | -0.3 (Oral Olanzapine) | — | wk 104 · n 121 | NCT00320489 Phase 3, secondary |
| Olanzapine/samidorphan (Lybalvi) | -1.2 | -0.8 | −0.4 | wk 4 · n 132 | NCT02634346 Phase 3, secondary |
| Paliperidone (Invega) | 0 | 0 | ±0 | wk 6 · n 54 | NCT00518323 Phase 3, secondary |
| Paliperidone palmitate (Invega Sustenna) | -1 | 0 | −1 | 150 mg eq. · wk 13 · n 160 | NCT00590577 Phase 3, secondary |
| Paliperidone palmitate (Invega Trinza) | 0 | 0 (PP3M) | — | wk 52 · n 475 | NCT03345342 Phase 3, secondary |
| Perseris | 0 | -0.3 | +0.3 | wk 4.14 · n 408 | NCT02203838 Phase 3, secondary |
| Pimavanserin | -0.8 | -0.7 | −0.1 | wk 6 · n 193 | NCT02970292 Phase 3, secondary |
| Quetiapine (Seroquel XR) | -1.4 | -0.9 | −0.5 | wk 6 · n 150 | NCT01810380 Phase 3, secondary |
| Quetiapine (Seroquel) | -1.4 | -0.9 | −0.5 | wk 6 · n 150 | NCT01810380 Phase 3, secondary |
| Rasagiline (Azilect) | 4.1 | 4.3 | −0.2 | wk 4 · n 26 | NCT00492336 Phase 4, secondary |
| Risperidone (Risperdal Consta) | -0.3 | 0.1 (Quetiapine) | — | wk 104 · n 326 | NCT00216476 Phase 3, secondary |
| Risperidone (Risperdal) | -0.9 | -0.5 | −0.4 | 120 mg · wk 8 · n 114 | NCT02109562 Phase 3, secondary |
| Roluperidone | -0.3 | -0.1 | −0.2 | 64 mg · wk 4 · n 171 | NCT03397134 Phase 3, secondary |
| Ulotaront | -0.9 | -0.8 | −0.2 | 100 mg · wk 6 · n 152 | NCT04092686 Phase 3, secondary |
| Xanomeline/trospium chloride | -0.6 | -0.5 | −0.1 | wk 6 · n 190 | NCT05145413 Phase 3, secondary |
| Ziprasidone | -1.2 | -1.2 (Haloperidol) | — | wk 0.43 · n 188 | NCT00723606 Phase 3, secondary |
Drugs checked with no result here: 48 not reported, 10 trial running, 10 not posted.
PANSS response
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Aripiprazole (Abilify Maintena) | 37% | 14.3% | +22.7 | 400/300 mg · wk 10 · n 162 | NCT01663532 Phase 3, secondary |
| Asenapine | 39.3% | 20.7% | +18.6 | 5 mg BID · wk 6 · n 173 | NCT01098110 Phase 3, secondary |
| Brexpiprazole (Rexulti) | 38.5% | 31.7% | +6.8 | 2 mg · wk 6 · n 179 | NCT01393613 Phase 3, secondary |
| Cannabidiol (Epidiolex) | 28.6% | 13.6% | +15 | 1000 mg/Day · wk 6.14 · n 42 | NCT02006628 Phase 2, primary |
| Olanzapine (Zyprexa) | 31.7%a | 44.7% (amisulpride) | — | — | NCT03510325 Phase 3, primary |
| Paliperidone (Invega) | 67.9% | 76.3% (Aripiprazole) | — | wk 8 · n 112 | NCT01009047 Phase 3, secondary |
| Quetiapine (Seroquel XR) | 62.7% | 32.1% | +30.6 | wk 6 · n 150 | NCT01810380 Phase 3, secondary |
| Quetiapine (Seroquel) | 62.7% | 32.1% | +30.6 | wk 6 · n 150 | NCT01810380 Phase 3, secondary |
| Ulotaront | 64.6% | 44% | +20.6 | wk 4 · n 96 | NCT02969382 Phase 2, secondary |
Drugs checked with no result here: 51 not reported, 13 trial running, 21 not posted.
PSP, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Aripiprazole (Abilify Maintena) | 12.3 | 5.2 | +7.1 | 400/300 mg · wk 10 · n 139 | NCT01663532 Phase 3, secondary |
| Brexpiprazole (Rexulti) | 10.5 | 8.5 | +2 | 2 mg · wk 6 · n 170 | NCT01393613 Phase 3, secondary |
| Olanzapine (Weltruza) | 10.6 | 5.6 | +5 | 531 mg · wk 8 · n 165 | NCT05693935 Phase 3, secondary |
| Paliperidone (Invega) | 12.2 | 12.2 (Aripiprazole) | — | wk 8 · n 112 | NCT01009047 Phase 3, secondary |
| Paliperidone palmitate (Invega Sustenna) | 8.3 | 1.7 | +6.6 | 150 mg eq. · wk 13 · n 160 | NCT00590577 Phase 3, secondary |
| Paliperidone palmitate (Invega Trinza) | 1 | 1.1 (PP3M) | — | wk 52 · n 473 | NCT03345342 Phase 3, secondary |
| Pimavanserin | 6.8 | 5.7 | +1.1 | wk 6 · n 193 | NCT02970292 Phase 3, secondary |
| Quetiapine (Seroquel XR) | 15.3 | 9.4 | +5.9 | wk 6 · n 138 | NCT01810380 Phase 3, secondary |
| Quetiapine (Seroquel) | 15.3 | 9.4 | +5.9 | wk 6 · n 138 | NCT01810380 Phase 3, secondary |
| Risperidone (Risperdal Consta) | 5.3 | 6.0 (Risperidone Tablets) | — | wk 52 · n 17 | NCT00992407 Phase 4, primary |
| Roluperidone | 3.2 | 1.2 | +2 | 64 mg · wk 4 · n 162 | NCT03397134 Phase 3, secondary |
| Xanomeline/trospium chloride | 5.3 | 5.9 | −0.6 | wk 6 · n 190 | NCT05145413 Phase 3, secondary |
Drugs checked with no result here: 51 not reported, 13 trial running, 18 not posted.
Relapse (% of patients) (maintenance)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Aripiprazole (Abilify Maintena) | 10% | 39.6% | −29.6 | wk 52 · n 269 | NCT00705783 Phase 3, secondary |
| Aripiprazole (Abilify) | 19.4% | 37.5% | −18.1 | wk 52 · n 98 | NCT01149655 Phase 3, primary |
| Brexpiprazole (Rexulti) | 13.5% | 38.5% | −24.9 | wk 52 · n 96 | NCT01668797 Phase 3, secondary |
| Lumateperone | 16.4%a | 38.6% | −22.2 | — | NCT04959032 Phase 3, primary |
| Lurasidone | 20.9% | 26.6% (Quetiapine) | — | wk 52 · n 139 | NCT00789698 Phase 3, primary |
| Olanzapine (Zyprexa Relprevv) | 20.1% | 18.5% (Oral Olanzapine) | — | n 264 | NCT00320489 Phase 3, secondary |
| Risperidone (Risperdal Consta) | 5% | 32.6% (Risperidone) | — | wk 52 · n 40 | NCT00330551 Phase 4, primary |
| Risperidone (Uzedy) | 7.1% | 29.3% | −22.2 | q1m · n 183 | NCT03503318 Phase 3, primary |
Drugs checked with no result here: 52 not reported, 14 trial running, 20 not posted.
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 94 approved or late-stage drugs with a featured trial in Schizophrenia were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.